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ABSTRACT 
Due to their higher risk of morbidity and perioperative mortality compared to younger patients, 
elderly patients with advanced ovarian cancer are challenging to treat. A population-based analysis 
was performed to predict treatment outcomes and establish risk factors for early death of elderly 
patients with advanced ovarian cancer using a cohort of 3,994 women diagnosed with Stage III or 
IV ovarian cancer between 1992 and 1999, registered with the Surveillance, Epidemiology and End 
Results (SEER) Cancer Registries. A multivariate accelerated failure-time model allowed 
estimation of a risk factor model for overall survival. Patient’s age, stage at presentation, presence 
of co-morbidities and oncology treatment facility were independently associated with overall 
survival at 12 months from diagnosis. Patients were assigned to low- (0-7 points), moderate- (8-14 
points) or high- (≥15 points) risk groups according to accumulation of risk factors, which showed 
good ability to predict 12-month mortality (ROC derivation cohort = 0.763; ROC validation cohort 
= 0.756).  Across all three risk groups patients who received both, surgery and chemotherapy 
showed significantly improved survival as compared to patients who received only surgery or 
chemotherapy. For patients 80 years and over who had upfront surgery, perioperative mortality was 
significantly greater in the high-risk group (21%; 95% CI = 16%-26%) compared to patients within 
the moderate- (8%; 95% CI = 5%-12%) and low-risk groups (0%; 95% CI = 0%-11%). The risk 
factor profile established could be helpful to plan future clinical trials to establish optimal treatment 
for elderly patients with advanced stage ovarian cancer.  
 
 
KEY WORDS: ovarian cancer, elderly patients, survival, treatment, outcome
 3
Ovarian cancer is the sixth most common cancer in women in the USA, Australia and Europe. The 
majority (1) of the 20,180 patients expected to be diagnosed with ovarian cancer in 2006 in the USA 
(2) will present with stage III or IV disease, and 20% will be diagnosed 75 years or older (3). Both the 
risk of ovarian cancer and comorbidities  increase with age (4). Decisions to limit treatment and to 
exclude elderly patients from clinical trials are often made under the assumptions that a) treatment-
associated morbidity and perioperative mortality would be unacceptably high, and b) the benefit of 
radical treatment would be very low, particularly in the presence of competing causes of mortality 
(5-7). However, given an aging US population (8) and the non-linear relationship between age and life 
expectancy (9), more needs to be known about the impact of epithelial ovarian cancer and the risk-
to-benefit ratio for treatment options available to patients. In particular, from a clinical point of 
view, treatment decisions for those aged ≥ 80 years are difficult.  
Linkage of clinical treatment and outcomes data available through the Surveillance, Epidemiology 
and End Results (SEER) Cancer Registry with Medicare claims has provided important insight into 
the treatment and outcomes of ovarian cancer patients (3, 10-15), however, none of these previous 
studies has focused on the question of predicting outcomes for patients 65 years or older. Mortality 
from ovarian cancer increases with patients’ age (3), possibly due to older patients being less likely 
to receive optimal treatment according to current guidelines (10) and presenting at later stages (3, 16). 
In contrast, elderly patients themselves express a strong wish to receive radical, curative treatment 
(17, 18), and some studies have found equivalent outcomes irrespective of patient’s age recently (19).  
Considering that few studies to date assessed expected outcomes among patients 65 years and older 
with advanced ovarian cancer who did or did not receive standard treatment (20), our aims were 
threefold: first, to describe the life-expectancy of elderly patients presenting with stage III or IV 
ovarian cancer in relation to patient and treatment characteristics; second, to establish risk factors 
for survival probability of less than 12 months from diagnosis and to describe the treatment 
outcomes for patients with increasing number of risk factors depending on whether or not standard 
treatment was received; third, to validate these risk factors within a validation cohort; and fourth to 
investigate outcomes for patients 80 years and over in particular.  
MATERIALS AND METHODS 
Details of the representativeness of the SEER data (14% of the US population), its quality and 
accuracy of linkage with Medicare are described elsewhere (21-25).  
Following approval by the appropriate National Cancer Institute’s (NCI) SEER committee, data 
were received for all patients diagnosed with ovarian cancer (ICD-O-2 code =C56) between 1992 
and 1999 (follow-up to 2002) (n = 13,596). Patients ≥ 65 years at diagnosis with histology of 
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epithelial ovarian cancer (histology code = 8000, 8010, 8052, 8260, 8310, 8140, 8440, 8441, 8450, 
8460, 8461, 8470, 8471, 8480, 8481 or 8570) and FIGO stage III or IV (n=5,633) were eligible. 
Patients were excluded if they were not covered by Medicare parts A and B or were a member of a 
Health Maintenance Organisation (HMO) at any time from 12 months prior to diagnosis of ovarian 
cancer to 12 months after diagnosis (or up until time of death) (n=1,639). All analyses were 
conducted using the statistical package SAS® version 9.1.2 (SAS Institute Inc. Cary, NC).   
Eligible patients were randomly divided into a derivation and validation cohort, evenly distributed 
by age, to derive and validate a survival risk score. The similarities of key characteristics such as 
age, treatment received and co-morbidities of the patients in the two cohorts were compared using 
chi-squared tests.  Bivariate hazard ratios for 1-month, 1-year and 3-year mortality and median 
survival times associated with these characteristics were calculated for the derivation cohort.  
We established if patients had cardiovascular (ICD-9-CM codes 390-459 inclusive), respiratory 
(460-519), renal (580-589) or endocrine (240-279) co-morbidities recorded on the Medicare dataset 
within the 12 months prior to or four months following month of diagnosis for ovarian cancer. 
Rather than using a co-morbidity index, (26) we selected these disease groups as they are essential 
when determining eligibility for surgery and/or chemotherapy. For chemotherapy, we extracted 
ICD-9-CM diagnosis (codes V581, V662, V672, E9331 and E9307) and procedure (code 9925) data 
contained in the SEER-Medicare Provider Analysis and Review (MEDPAR) dataset and 
chemotherapy drug usage (Healthcare Common Procedure Coding System (HCPCS) codes J9000-
J9999, 96400-96599 and Q0083-Q0085) from the SEER-National Claims History dataset.  
Chemotherapy records were matched if they occurred within the month of diagnosis for ovarian 
cancer and up to six months afterwards, to exclude chemotherapy received for other cancers and 
recurrences. The NCI’s Hospital File allowed us to assess if treatment was received within a NCI 
approved Comprehensive Cancer Center, other large (≥300 beds), or small hospital (<300 beds), or 
whether no hospital treatment was recorded within the first six months after diagnosis.  
The SEER Registry does not record an exact date of diagnosis.  Therefore, survival was calculated 
in months, and was estimated from the 15th day of the month of diagnosis to the exact date of 
death.  For patients who received surgery, death within one month of diagnosis was defined as a 
surrogate for perioperative mortality (commonly defined as death within 30 days after surgery).  
Statistical Procedures 
Adjusted hazard ratios for 1-year mortality within the derivation cohort were based on an 
accelerated failure time model and computed using the LIFEREG procedure with the error term 
specified as following a Weibull distribution.  Non-significant explanatory variables were removed 
from the model. All analyses were adjusted for tumour grade and year of treatment. The likelihood 
 5
ratio test statistic revealed a highly significant difference (p<0.001) between the fit of the null 
model and the fit of the multivariate risk factor model including the explanatory and adjustment 
variables.  The relative influence of each risk factor was determined by dividing the parameter 
estimate (i.e. β before it is transformed into hazard ratios) for each statistically significant (p<0.05) 
co-variate by the lowest significant parameter estimate (for cardiovascular morbidity) and then 
rounding to the nearest integer (27).  These components were then summed to derive a risk grouping 
for elderly patients. Type of treatment was highly significant in the bivariate analysis as expected, 
and patients within different risk groups were stratified depending on whether they received 
standard treatment, surgery only, chemotherapy only or no treatment.   .  
Logistic regression analysis was conducted to assess the ability of the resulting risk groups to 
predict 1-year and 3-year survival, by assessing the area under the receiver-operator characteristics 
curve (ROC) separately within the derivation cohort and the validation cohort. All patients from 
both cohorts were subsequently divided into three groups (low-, moderate- and high- risk group) to 
achieve a distribution of 25%, 50% and 25%, respectively, depending on the number of risk factors  
(0-7, 8-14, and ≥15, respectively), and Kaplan-Meier survival curves were produced for each risk 
group stratified by type of treatment. The risk score was applied to describe perioperative mortality 
for patients aged ≥ 80 years. 
RESULTS 
The random procedure to obtain the derivation and validation cohorts resulted in equivalent 
distribution (Table 1). Thirty percent of all patients were ≥ 80 years at the time of diagnosis, 88% 
were Caucasian, more than 60% lived in large metropolitan areas. Forty-nine percent of patients 
were diagnosed with stage III ovarian tumours, and 40% of patients were diagnosed with grade 3 
(poorly differentiated) tumours (grade unknown for 37%). Only 7% of patients received treatment 
within a NCI Comprehensive Cancer Center. With regards to treatment, for 23% of patients neither 
surgery nor chemotherapy was recorded, 14% received chemotherapy only, 22% surgery only and 
41% of patients received surgery plus chemotherapy. Cardiovascular and endocrine co-morbid 
conditions were most common, recorded for 55%-60% of patients, 20% of patients had no co-
morbidity. Median survival was 14 months in the derivation and 15 months in the validation cohort. 
Bivariate analysis  
Within the derivation cohort, the unadjusted risk of dying within 12 months from diagnosis was 
associated with increasing age, Stage IV disease, treatment at facilities other than a NCI 
Comprehensive Cancer Center, treatment other than a combination of chemotherapy and surgery 
and the presence of co-morbidity (Table 2). Figure 1 depicts the magnitude of differences in median 
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survival by the most prominent factors in the bivariate analysis. Kaplan Meier survival curves for 
the age groups 80 to 84 years and ≥ 85 years, depending on treatment received, are presented in 
Figure 2. 
Multivariate analysis 
Within the multivariate model, age and stage at diagnosis, the presence co-morbidities, and 
treatment facility were significantly associated with overall survival at 12 months (adjusted for 
tumour grade and year of diagnosis). Depending on the strengths of association, the risk score for 
these components varied in their value from 1 for cardiovascular co-morbidity to 11 for age ≥ 85 
years (Table 3). Exemplifying the risk grouping on a patient who presents at age 85 years (risk 
value 11) with stage IV disease (risk value 4) at a small hospital (risk value 3) with a renal co-
morbidity (risk value 6) would result in a risk score of 11+4+3+6=24 or the high risk group. 
The derived risk score discriminated ovarian cancer patients’ risk of death from any cause within 
the first 12 months from diagnosis equally well within the derivation (ROC area = 0.763) and 
validation (ROC area = 0.756) cohorts. 
Within each risk group, patients who received neither surgery nor chemotherapy had the lowest 
overall one year survival (23% in the low-risk group, 14% in the moderate-risk group, and 6% in 
the high-risk group). Conversely, within each of the risk-score groups, patients who received both 
chemotherapy and surgery had the highest survival (89% in the low-risk group, 78% in the 
moderate-risk group, and 62% in the high-risk group) (Figure 3). 
For patients ≥ 80 years who received surgery, perioperative mortality was 0% (95% CI = 0%-12%), 
9% (95% CI = 5%-13%), and 21% (95% CI = 16%-26%) in the low-, moderate-, and high-risk 
groups, respectively (Figure 4).  
 
DISCUSSION 
The present investigation, by using a derivation and validation cohort, provides reference data for 
survival among elderly patients diagnosed with stage III or IV epithelial ovarian cancer. For these 
patients, advanced age, FIGO stage IV, presence of selected co-morbidities and treatment outside 
large and/or specialised oncology facilities predict the risk of death within the first 12 months 
following diagnosis of ovarian cancer. However, irrespective of this, the strongest risk factor for 
death within one year of diagnosis was receiving other than standard treatment (i.e. a combination 
of chemotherapy plus surgery).  
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The diagnosis and treatment of elderly patients in particular those 80 years or older with advanced 
ovarian cancer provides a challenge for the clinician. It is common for elderly patients to overlook 
the unspecific symptoms of ovarian cancer, possibly attributing these to normal signs of aging or 
pre-existing morbidities (28). This incurs a greater risk of elderly patients presenting with late disease 
compared to younger patients (7), thus reducing prevalence of treatment according to the NIH 
Consensus Development Conference guidelines (10). In the past it has been established that there are 
differences in the treatment of patients with ovarian cancer by age and race and whether patients 
received their treatment in a high volume treatment institution and by a gynaecologic oncologist  (10, 
12, 14, 29-31). The present study extracts the impact of divergence from standard treatment for patients 
with low, medium and high accumulation of risk factors.  
Taking into account comorbidities, stage and treatment facilities allows significantly better 
predictions of one-year survival compared to those based on age alone. Further to this, the risk score 
is also predictive of peri-operative mortality in patients of ≥ 80 years. A patient of ≥ 80 years 
without any other risk factor will enter the low-risk group, indicating that peri-operative risk is low, 
and can expect significant benefit if standard treatment including cytoreductive surgery is received. 
Similarly, patients ≥ 85 years with no, or only a minor, additional risk factor will be allocated to the 
moderate-risk group, for whom peri-operative mortality is still estimated to be around 9%. If no 
treatment is given, the median survival within the 80-84 and ≥ 85 years age groups is lowest in any 
case and expected to be 3 months and 2 months, respectively, compared with over 20 months if 
both surgery and chemotherapy are received (Figure 2).  However, there is a clear linear trend 
towards higher peri-operative mortality once patients reach a risk score of 15 or over (high-risk 
group) as depicted in Figure 4. For these patients, upfront surgery may not be the most appropriate 
first option and the value of neo-adjuvant chemotherapy is currently being investigated in 
randomized controlled trials (32). 
We did not attempt to replicate recent results derived for a SEER cohort demonstrating better 
outcomes if treatment was provided by gynaecologic oncologists (13). We found, however, that 
patients with advanced ovarian cancer who were treated within larger treatment facilities had a 
significantly lower risk of dying within 12 months of diagnosis compared to patients treated at other 
hospitals with fewer than 300 beds. Larger treatment units may be more likely to participate in 
research protocols and provide additional support services, commonly associated with better 
outcomes. This is also reflected in the National Comprehensive Cancer Network Senior Adult 
Oncology guidelines, which state that the best management for cancer patients will be within 
clinical trials (33).  Greater case-load has also been associated with better outcome in some, but not 
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all studies (14, 34). Specialised gynaecologic oncologists are also more likely to work in larger centres 
(13, 30). 
Several limitations of the present cohort study should be noted.  Due to the nature of this 
observational data, treatment could not be randomly allocated, and therefore each patient’s outcome 
was affected not only by components of their risk score, but also by the treatment that they received 
as clearly demonstrated in the unadjusted analyses (Table 2). The value of assigning patients a risk 
score and using it to predict likely outcome if standard treatment or alternative treatment regimens 
are chosen now needs to be confirmed in prospective studies. The SEER-Medicare Registries 
collect summarised claims data and therefore are subject to inaccuracies during coding and 
limitations in the number of codes that can be provided per patient. For example, for co-morbidities 
some may not be recorded if other, more acute codes are filling all 10 available coding spaces (26). 
The nature of our investigation did not allow us to determine if patients who received no treatment 
refused treatment or were not offered surgery and/or chemotherapy. Similarly, it is unclear if 
comorbidities resulted in death before treatment could be initiated, if patients with comorbidities 
were more likely to refuse treatment, or doctors recommended against treatment in their presence. 
Despite these limitations, the relatively large dataset, and the similar performance of the risk score 
in both the derivation and validation cohorts, give confidence in the robustness of the results. In 
addition, similar issues have recently been raised with regards to treatment and survival among 
other cohorts of elderly cancer patients and cancer patients with comorbidities (35, 36). 
In summary, in the presence of a deadly disease, such as advanced ovarian cancer, in a vulnerable 
patient population, such as elderly patients with comorbidities, a fine line separates beneficial and 
harmful medical interventions. Our results provide reference data and suggest that even patients 80 
years and older who have a low or moderate risk score can benefit from treatment according to 
guidelines for high-quality ovarian cancer care. Given the recommendations by the National 
Comprehensive Cancer Network Senior Adult Oncology guidelines, advancing our knowledge by 
enrolling elderly patients into clinical trials to assess the value of standard treatment against 
intensity-modified protocols seems to be the most promising way forward.   
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Table 1  Selected characteristics for the derivation and validation cohorts 
Cohort 
Derivation Validation 
 
 
Covariates Number % Number % 
Chi-
square 
p-value a 
Total cohort 1998 100.0 1996 100.0  
  
Age group(yrs)  1.00 
65-69  382 19.1 381 19.1  
70-74  516 25.8 515 25.8  
75-79  492 24.6 492 24.6  
80-84  339 17.0 339 17.0  
85 years and older 269 13.5 269 13.5  
Race  0.78 
Caucasian 1752 87.7 1744 87.4  
Black 113 5.7 105 5.3  
Hispanic 76 3.8 82 4.1  
Other 57 2.9 65 3.3  
Locality type b  0.77 
Large metropolitan 1237 61.9 1241 62.2  
Metropolitan 425 21.3 408 20.4  
Non-metropolitan 336 16.8 347 17.4  
  
First primary cancer  0.66 
Yes 1711 85.6 1720 86.2  
No 287 14.4 276 13.8  
  
Stage of tumour (FIGO)  0.24 
Stage III 957 47.9 994 49.8  
Stage IV 1041 52.1 1002 50.2  
  
Grade of tumour (ICD-O-2)  0.48 
Grade 1 – well differentiated 44 2.2 56 2.8  
Grade 2 – moderately differentiated 262 13.1 266 13.3  
Grade 3 – poorly differentiated 792 39.6 784 39.3  
Grade 4 – undifferentiated 140 7.0 160 8.0  
Unknown 760 38.0 730 36.6  
  
Year of diagnosis  0.96 
1992-1993 554 27.7 540 27.1  
1994-1995 492 24.6 502 25.2  
1996-1997 487 24.4 489 24.5  
1998-1999 465 23.3 465 23.3  
  
Treatment facility c  0.31 
NCI- Comprehensive Cancer Center 127 6.4 156 7.8  
Other hospital/facility with 300+ beds 1128 56.5 1099 55.1  
Other hospital/facility with <300 beds 600 30.0 606 30.4  
Facility unknown/no facility recorded 143 7.2 135 6.8  
  
Treatment group d  0.56 
Neither chemotherapy nor surgery 442 22.1 477 23.9  
Chemotherapy only 281 14.1 269 13.5  
Surgery only 444 22.2 424 21.2  
Both chemotherapy and surgery 831 41.6 826 41.4  
  
Selected comorbid conditions   
Cardiovascular diseases 1182 59.2 1175 58.9 0.88 
Respiratory diseases 711 35.6 706 35.4 0.91 
Renal diseases 101 5.1 103 5.2 0.94 
Endocrine, nutritional or metabolic 
diseases or immunity disorders 
1123 56.2 1124 56.3 0.97 
  
Number of selected comorbid conditions  0.80 
0 388 19.4 407 20.4  
1 557 27.9 533 26.7  
2 633 31.7 631 31.6  
3 or 4 420 21.0 425 21.3  
  
Survival time following diagnosis   
Survived for 1 month 1716 85.9 1687 84.5 0.24 
Survived for 1 year 1044 52.3 1053 52.8 0.77 
Survived for 3 years 487 24.4 495 24.8 0.78 
Median survival time (95% CI) e 14 months (13-15) 15 months (13-16)  
a. p-values shown for 2x2 tables are for continuity adjusted chi-square tests. 
b. Locality type is based on place of usual residence at time of first diagnosis of cancer when aged 65 years or older. 
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c. Admitted to facility for treatment within 6 months of diagnosis with ovarian cancer.   
d. Chemotherapy treatment received within 6 months of diagnosis with ovarian cancer. 
e. Survival time for women who were still alive was censored at Dec 31 2002.
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Table 2  1-month, 1-year and 3-year survival bivariate hazard ratios and median survival time by selected characteristics within the derivation cohort 
(n=1,998) 
 
1-month survival 1-year survival 3-year survival Median survival  
 
 
Covariates 
Crude 
Hazard 
Ratios 
 
 
95% CI 
 
 
p-value 
Crude 
Hazard 
Ratios 
 
 
95% CI 
 
 
p-value
Crude 
Hazard 
Ratios 
 
 
95% CI 
 
 
p-value
Median 
survival 
(months) a 
 
 
95% CI 
            
Age group (yrs) Wald chi-square = 149.89;  df = 4;  p < 0.001 Wald chi-square = 359.42;  df = 4;  p < 0.001 Wald chi-square = 350.21;  df = 4;  p < 0.001   
65-69  1.00   1.00   1.00   27 (23-29) 
70-74 1.82 (1.04-3.17)   0.04 1.47 (1.16-1.87)   0.002 1.35 (1.14-1.59)   0.001 21 (18-24) 
75-79  4.06 (2.39-6.89) <0.001 2.26 (1.79-2.85) <0.001 1.83 (1.55-2.16) <0.001 14.5 (12-17) 
80-84  4.85 (2.80-8.40) <0.001 3.58 (2.82-4.54) <0.001 2.47 (2.07-2.94) <0.001 7 (6-9) 
85 years and older 14.46 (8.35-25.0) <0.001 7.04 (5.53-8.95) <0.001 4.64 (3.87-5.55) <0.001 2 (2-3) 
            
Race Wald chi-square = 0.57;  df = 3;  p = 0.902 Wald chi-square = 6.89;  df = 3;  p = 0.075 Wald chi-square = 6.94;  df = 3;  p = 0.074   
Caucasian 1.00   1.00   1.00   14.5 (13-16) 
Black 1.10 (0.66-1.83)   0.70 1.38 (1.07-1.78)   0.01 1.28 (1.03-1.57)   0.02 9 (5-13) 
Hispanic 0.99 (0.52-1.86)   0.97 1.15 (0.83-1.59)   0.39 1.17 (0.90-1.51)   0.24 12.5 (7-18) 
Other 1.24 (0.66-2.34)   0.50 1.07 (0.74-1.55)   0.71 0.89 (0.65-1.23)   0.49 11 (7-27) 
            
Locality type b Wald chi-square = 0.34;  df = 2;  p = 0.844 Wald chi-square = 3.15;  df = 2;  p = 0.207 Wald chi-square = 1.41;  df = 2;  p = 0.493   
Large metropolitan 1.00   1.00   1.00   14 (12-16) 
Metropolitan 0.92 (0.68-1.24)   0.57 0.96 (0.82-1.13)   0.60 0.99 (0.87-1.12)   0.82 15 (12-18) 
Non-metropolitan 1.01 (0.73-1.39)   0.97 1.14 (0.96-1.35)   0.13 1.08 (0.94-1.24)   0.28 11.5 (9-15) 
            
First primary cancer Wald chi-square = 0.47;  df = 1;  p = 0.495 Wald chi-square = 0.02;  df = 1;  p = 0.883 Wald chi-square = 0.79;  df = 1;  p = 0.374   
Yes 1.00   1.00   1.00   14 (12-16) 
No 0.89 (0.62-1.26)   0.49 1.01 (0.85-1.22)   0.88 1.07 (0.93-1.23)   0.37 13 (10-16) 
            
Stage of tumour (FIGO) Wald chi-square = 35.45;  df = 1;  p < 0.001 Wald chi-square = 116.63;  df = 1;  p < 0.001 Wald chi-square = 116.56;  df = 1;  p < 0.001   
Stage III 1.00   1.00   1.00   21 (18-23) 
Stage IV 2.16 (1.68-2.78) <0.001 2.10 (1.84-2.41) <0.001 1.76 (1.59-1.95) <0.001 8 (7-10) 
            
Grade of tumour (ICD-O-2) Wald chi-square = 66.74;  df = 2;  p < 0.001 Wald chi-square = 173.65;  df = 2;  p < 0.001 Wald chi-square = 176.44;  df = 2;  p < 0.001   
Grades 1 and 2 1.00   1.00   1.00   22 (17-27) 
Grades 3 and 4 1.03 (0.68-1.55)   0.89 1.10 (0.89-1.36)   0.39 1.16 (0.99-1.36)   0.07 19 (17-21) 
Unknown 2.90 (1.95-4.33) <0.001 2.58 (2.10-3.18) <0.001 2.23 (1.90-2.62) <0.001 6 (5-7) 
            
Year of diagnosis Wald chi-square = 0.57;  df = 3;  p = 0.902 Wald chi-square = 5.85;  df = 3;  p = 0.119 Wald chi-square = 8.16;  df = 3;  p = 0.043   
1992-1993 1.02 (0.73-1.41)   0.92 1.05 (0.88-1.25)   0.59 0.95 (0.83-1.09)   0.49 11 (10-15) 
1994-1995 0.92 (0.66-1.30)   0.65 0.88 (0.73-1.06)   0.17 0.85 (0.73-0.98)   0.03 14 (13-16) 
1996-1997 1.05 (0.75-1.46)   0.79 0.89 (0.74-1.07)   0.20 0.84 (0.72-0.97)   0.02 15 (13-18) 
1998-1999 1.00   1.00   1.00   14 (11-16) 
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Table 2 (cont.)  1-month, 1-year and 3-year survival bivariate hazard ratios and median survival time by selected characteristics within the derivation 
cohort (n=1,998) 
 
1-month survival 1-year survival 3-year survival Median survival  
 
 
Covariates 
Crude 
Hazard 
Ratios 
 
 
95% CI 
 
 
p-value 
Crude 
Hazard 
Ratios 
 
 
95% CI 
 
 
p-value
Crude 
Hazard 
Ratios 
 
 
95% CI 
 
 
p-value
Median 
survival 
(months) a 
 
 
95% CI 
            
Treatment facility c Wald chi-square = 27.48;  df = 3;  p < 0.001 Wald chi-square = 36.95;  df = 3;  p < 0.001 Wald chi-square = 27.57;  df = 3;  p < 0.001   
NCI-Comprehensive Cancer Center 1.00   1.00   1.00   24 (18-30) 
Other hospital/facility with 300+ beds 1.82 (0.95-3.45)   0.07 1.62 (1.18-2.23)   0.003 1.44 (1.15-1.81)   0.002 16 (14-18) 
Other hospital/facility with <300 beds 2.34 (1.21-4.52)   0.01 2.17 (1.57-3.01) <0.001 1.68 (1.32-2.13) <0.001 10 (8-12) 
Facility unknown/no facility recorded 4.33 (2.13-8.81) <0.001 2.39 (1.64-3.49) <0.001 1.93 (1.45-2.57) <0.001 9 (5-14) 
            
Treatment group d Wald chi-square = 188.64;  df = 3;  p < 0.001 Wald chi-square = 742.52;  df = 3;  p < 0.001 Wald chi-square = 800.70;  df = 3;  p < 0.001   
Neither chemotherapy or surgery 210.05 (70.7-624.0) <0.001 15.28 (12.47-18.72) <0.001 6.64 (5.82-7.58) <0.001 2 (1-3) 
Chemotherapy only 25.16 (8.4-75.6) <0.001 4.53 (3.60-5.69) <0.001 2.54 (2.18-2.97) <0.001 11 (9-13) 
Surgery only 54.73 (18.7-160.0) <0.001 4.19 (3.40-5.17) <0.001 1.91 (1.66-2.20) <0.001 9 (7-12) 
Both chemotherapy and surgery 1.00   1.00   1.00   28 (26-30) 
            
Selected comorbid conditions      
Cardiovascular diseases Wald chi-square = 13.79;  df = 1;  p < 0.001 Wald chi-square = 40.27;  df = 1;  p < 0.001 Wald chi-square = 36.95;  df = 1;  p < 0.001   
No 1.00   1.00   1.00   18 (16-21) 
Yes 1.61 (1.25-2.07) <0.001 1.55 (1.35-1.77) <0.001 1.38 (1.24-1.53) <0.001 10 (9-12) 
Respiratory diseases Wald chi-square = 26.85;  df = 1;  p < 0.001 Wald chi-square = 56.85;  df = 1;  p < 0.001 Wald chi-square = 56.83;  df = 1;  p < 0.001   
No 1.00   1.00   1.00   17 (15-19) 
Yes 1.88 (1.48-2.40) <0.001 1.65 (1.45-1.87) <0.001 1.49 (1.34-1.65) <0.001 9 (7-10) 
Renal diseases Wald chi-square = 38.55;  df = 1;  p < 0.001 Wald chi-square = 73.56;  df = 1;  p < 0.001 Wald chi-square = 57.53; df = 1;  p < 0.001   
No 1.00   1.00   1.00   15 (14-16) 
Yes 3.38 (2.30-4.96) <0.001 2.78 (2.20-3.51) <0.001 2.28 (1.84-2.83) <0.001 2 (2-3) 
Endocrine, nutritional or metabolic 
diseases or immunity disorders Wald chi-square = 13.21;  df = 1;  p < 0.001 Wald chi-square = 62.72;  df = 1;  p < 0.001 Wald chi-square = 56.91;  df = 1;  p < 0.001   
No 1.00   1.00   1.00   19 (16-21) 
Yes 1.57 (1.23-2.01) <0.001 1.72 (1.50-1.97) <0.001 1.49 (1.34-1.65) <0.001 9 (8-11) 
            
a. Survival time for women who were still alive was censored as at Dec 31 2002. 
b. Locality type is based on place of usual residence at time of first diagnosis of cancer when aged 65 years or more. 
c. Admitted to facility for treatment within 6 months of diagnosis with ovarian cancer. 
d. Chemotherapy treatment received within 6 months of diagnosis with ovarian cancer.
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Table 3  Multivariate accelerated failure-time model to develop risk scores associated with  
1-year survival (derivation cohort, n=1,998) 
1-year survival  
 
Covariates a 
Adjusted 
Hazard Ratios 
 
95% CI 
 
p-value 
 
Risk Score b 
Risk Factors   
Age group (yrs) Wald chi-square = 266.68;  df = 4;  p < 0.001  
65-69  1.00   0 
70-74  1.53 (1.20-1.94)   0.001 3 
75-79  2.24 (1.77-2.82) <0.001 5 
80-84  3.18 (2.51-4.05) <0.001 7 
85 years and older 5.91 (4.63-7.55) <0.001 11 
  
Stage of tumour (FIGO) Wald chi-square = 80.47;  df = 1;  p < 0.001  
Stage III 1.00   0 
Stage IV 1.87 (1.63-2.14) <0.001 4 
  
Treatment facility c Wald chi-square = 19.04;  df = 3;  p < 0.001  
NCI-Comprehensive Cancer Center 1.00   0 
Other hospital/facility with 300+ beds 1.24 (0.90-1.71)   0.19 0 
Other hospital/facility with <300 beds 1.59 (1.14-2.21)   0.006 3 
Facility unknown/no facility recorded 1.71 (1.16-2.52)   0.007 3 
  
Cardiovascular diseases Wald chi-square = 5.36;  df = 1;  p = 0.021  
No 1.00   0 
Yes 1.18 (1.03-1.36)   0.02 1 
  
Respiratory diseases Wald chi-square = 35.93;  df = 1;  p < 0.001  
No 1.00   0 
Yes 1.51 (1.32-1.73) <0.001 2 
  
Renal diseases Wald chi-square = 64.16;  df = 1;  p < 0.001  
No 1.00   0 
Yes 2.63 (2.08-3.33) <0.001 6 
  
Endocrine, nutritional or metabolic 
diseases or immunity disorders Wald chi-square = 38.34;  df = 1;  p < 0.001 
 
No 1.00   0 
Yes 1.56 (1.36-1.80) <0.001 3 
Adjustment variables   
Grade of tumour (ICD-O-2) Wald chi-square = 66.81;  df = 2;  p < 0.001  
Grades 1 and 2 1.00    
Grades 3 and 4 1.09 (0.88-1.35)   0.42  
Unknown 1.87 (1.51-2.31) <0.001  
  
Year of diagnosis Wald chi-square = 16.70;  df = 3;  p = 0.001  
1992-1993 1.19 (0.99-1.42)   0.06  
1994-1995 0.89 (0.74-1.08)   0.23  
1996-1997 0.85 (0.70-1.02)   0.09  
1998-1999 1.00    
Likelihood ratio test statistic = 742.24; df = 17; p < 0.001. 
a.  Race, locality type, and first primary cancer were not statistically significant, and so were excluded from the final model.  Grade of 
tumour and year of diagnosis were included in the model as confounding variables only. 
b.  The risk score was calculated by dividing the parameter estimate (i.e. β before it is transformed into hazard ratios) for each 
category of each significant covariate by the lowest parameter estimate that was significant (i.e. women with cardiovascular 
disease) and rounding to the nearest integer.   
c.  Admitted to facility for treatment within 6 months of diagnosis with ovarian cancer.   
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Figure 1  Median survival time following diagnosis by selected characteristics in the 
derivation cohort (n = 1,998) 
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Figure 2  Kaplan-Meier survival curves for women aged 80 and over by type of treatment 
(derivation and validation cohorts combined)  
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1-year 
survival* 
(%) 
Median 
survival* 
(months) 
No surgery or 
chemotherapy 
240 7.9 
(4.9-11.8) 
2 
(2-3) 
Chemotherapy 
only 
95 46.3 
(36.1-55.9) 
11 
(6-16) 
Surgery only 159 35.8 
(28.5-43.3) 
4 
(3-7) 
Surgery and 
Chemotherapy 
184 72.8 
(65.8-78.7) 
23 
(20-26) 
* 95% confidence intervals shown in italicised brackets 
Log rank test for 1-year survival: 
Chi-square = 262.75; df = 3; p < 0.001 
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1-year 
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survival* 
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No surgery or 
chemotherapy 
301 7.0 
(4.5-10.2) 
2 
(1-3) 
Chemotherapy 
only 
72 30.6 
(20.4-41.3) 
8 
(5-11) 
Surgery only 127 26.8 
(19.4-34.7) 
4 
(2-6) 
Surgery and 
Chemotherapy 
38 63.2 
(45.9-76.3) 
22 
(12-33) 
* 95% confidence intervals shown in italicised brackets 
Log rank test for 1-year survival: 
Chi-square = 102.04; df = 3; p < 0.001 
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Figure 3  Kaplan-Meier survival curves by risk group and type of treatment (derivation and 
validation cohorts combined) 
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only 
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Surgery and 
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37 
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Log rank test for 1-year survival: 
Chi-square = 298.73; df = 3; p < 0.001 
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Chemotherapy 
only 
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(8-15) 
Surgery and 
Chemotherapy 
830 78.2 
(75.2-80.9) 
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(24-28) 
* 95% confidence intervals shown in italicised brackets 
Log rank test for 1-year survival: 
Chi-square = 689.55; df = 3; p < 0.001 
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chemotherapy 
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Chemotherapy 
only 
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(22.5-36.0) 
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Surgery only 222 19.4 
(14.5-24.8) 
3 
(2-3) 
Surgery and 
Chemotherapy 
169 62.1 
(54.4-69.0) 
18 
(15-21) 
* 95% confidence intervals shown in italicised brackets 
Log rank test for 1-year survival: 
Chi-square = 294.58; df = 3; p < 0.001 
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 Figure 4  1-month mortality by risk-score for women aged 80 years and older who had 
surgery 
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* 95% confidence intervals shown in 
italicised brackets 
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